Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design

被引:14
|
作者
Bellenie, Benjamin R. [1 ]
Barton, Nicholas P. [1 ]
Emmons, Amanda J. [1 ]
Heer, Jag P. [1 ]
Salvagno, Cristian [2 ]
机构
[1] GlaxoSmithKline Inc, Harlow CM19 5AD, Essex, England
[2] GlaxoSmithKline SpA, Med Res Ctr, Verona, Italy
关键词
Oxytocin antagonist; Cresset FieldScreen; Oxytocin; Vasopressin; Molecular field; Hit discovery; Structure-based drug design; PRETERM; POTENT; LABOR;
D O I
10.1016/j.bmcl.2008.11.064
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel oxytocin antagonist was identified by 'scaffold-hopping' using Cresset FieldScreen molecular field similarity searching. A single cycle of optimization driven by an understanding of the key pharmacophoric elements required for activity led to the discovery of a potent, selective and highly ligand-efficient oxytocin receptor antagonist. Selectivity over vasopressin receptors was rationalized based on differences in the structure of the natural ligands. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:990 / 994
页数:5
相关论文
共 50 条
  • [1] Ligand- and Structure-Based Drug Design and Optimization using KNIME
    Mazanetz, Michael P.
    Goode, Charlotte H. F.
    Chudyk, Ewa, I
    [J]. CURRENT MEDICINAL CHEMISTRY, 2020, 27 (38) : 6458 - 6479
  • [2] Structure-Based Design of Potent and Ligand-Efficient Inhibitors of CTX-M Class A β-Lactamase
    Nichols, Derek A.
    Jaishankar, Priyadarshini
    Larson, Wayne
    Smith, Emmanuel
    Liu, Guoqing
    Beyrouthy, Racha
    Bonnet, Richard
    Renslo, Adam R.
    Chen, Yu
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) : 2163 - 2172
  • [3] Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery
    Hunter, William N.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (18) : 11749 - 11753
  • [4] The role of structure-based ligand design and molecular modelling in drug discovery
    Tollenaere, JP
    [J]. PHARMACY WORLD & SCIENCE, 1996, 18 (02): : 56 - 62
  • [5] Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists
    Han, Zhenfu
    Pinkner, Jerome S.
    Ford, Bradley
    Obermann, Robert
    Nolan, William
    Wildman, Scott A.
    Hobbs, Doug
    Ellenberger, Tom
    Cusumano, Corinne K.
    Hultgren, Scott J.
    Janetka, James W.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (12) : 4779 - 4792
  • [6] THE INTEGRATION OF STRUCTURE-BASED DRUG DESIGN & COMBINATORIAL CHEMISTRY FOR EFFICIENT DRUG DISCOVERY
    Salemme, F. Raymond
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 1996, 52 : C4 - C4
  • [7] Structure-based drug design remains a key method for drug discovery and optimization
    Glaser, V
    [J]. GENETIC ENGINEERING NEWS, 1996, 16 (12): : 1 - &
  • [8] Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity
    Nordqvist, Anneli
    O'Mahony, Gavin
    Friden-Saxin, Maria
    Fredenwall, Marlene
    Hogner, Anders
    Granberg, Kenneth L.
    Aagaard, Anna
    Backstrom, Stefan
    Gunnarsson, Anders
    Kaminski, Tim
    Xue, Yafeng
    Dellsen, Anita
    Hansson, Eva
    Hansson, Pia
    Ivarsson, Ida
    Karlsson, Ulla
    Bamberg, Krister
    Hermansson, Majlis
    Georgsson, Jennie
    Lindmark, Bo
    Edman, Karl
    [J]. CHEMMEDCHEM, 2017, 12 (01) : 50 - 65
  • [9] Structure-based ligand design to overcome CYP inhibition in drug discovery projects
    Branden, Gisela
    Sjogren, Tove
    Schnecke, Volker
    Xue, Yafeng
    [J]. DRUG DISCOVERY TODAY, 2014, 19 (07) : 905 - 911
  • [10] Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
    Huang, Hung-Jin
    Lee, Kuei-Jen
    Yu, Hsin Wei
    Chen, Chien-Yu
    Hsu, Chih-Ho
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Chen, Calvin Yu-Chian
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2010, 28 (01): : 23 - 37